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j ourna l homepage: www.eb iomed ic ine.comEditorialEBioMedicine: Bridging Two Cultures to Improve HealthWest Africa is currently in the grip of the worst outbreak of Ebola
virus in documented history, eclipsing past outbreaks in terms of both
the number of people infected and the number of fatalities. In the
38 years since thediscovery of the virus,we still do not have an effective
vaccine or antiviral treatment for this devastating pathogen, although at
least three vaccines are in development. As with many neglected tropi-
cal diseases, Ebola has not historically been considered amajor interna-
tional public health priority. Sentiment is now clearly changing, and the
urgency regarding the need for prevention and treatment in response to
this virus is now being recognized as cases and virus transmission are
being seen in non-African countries.
We are launching EBioMedicine as a centralized forum where clini-
cians and scientists in both the clinic and the laboratory can communi-
cate their observations, ideas, and research insights—andwork together
to address outbreaks such as Ebola and other major biomedical health
challenges. With speciﬁc regard to the Ebola crisis we would, for exam-
ple, consider primary research papers looking at evolutionary mecha-
nisms of pathogenesis or viral drug response and resistance; studies
identifying new targetable pathogen vulnerabilities and vaccine strate-
gies; new screening approaches; analyses of disease transmission, pro-
gression and recovery; and opinion pieces about why this outbreak is
so severe. In this inaugural issue, we are pleased to present an In Focus
commentary from Kawaoka, Feldmann, and colleagues, who highlight
vaccine and treatment challenges facing both basic and clinical re-
searchers working on the current Ebola threat.
However, EBioMedicine's scope is not limited to viral outbreaks. The
journal will also cover the entire spectrum of biomedical research—we
will consider basic and clinical research papers addressing, but not lim-
ited to, the general subjects of cancer, microbiology, immunology, the
microbiome,metabolism, obesity, cardiovascular disease, diabetes, neu-
rodegenerative and neurodevelopmental diseases, stroke, allergy, auto-
immunity, inﬂammatory bowel diseases, vaccine design, regenerative
medicine, and aging.Wewill also consider papers discussing technolog-
ical approaches to expediting and applying research insights such as
bioinformatics, imaging, and personalized medicine; -omics research;http://dx.doi.org/10.1016/j.ebiom.2014.10.007
2352-3964/© 2014 The Author. Published by Elsevier B.V. This is an open access article underand whole-genome sequencing studies. We expect our scope to be dy-
namic and broad, inextricably tied to the evolution and emergence of
biomedical health concerns, but always focused on bringing scientists
and physicians together to transform information to action in improving
human health.
EBioMedicine is a translational journal, but how do we deﬁne trans-
lational research? Technology has become so powerful and so nimble
that personalized whole-genome sequencing is likely to be within our
reach as a practical clinical tool. For example, clinicians may now use
genomic screening to stratify cancer patients into groups that might
beneﬁt from targeted, gene-speciﬁc treatments that are in turn derived
from recent basic science advances in the underlying biology of those
altered genes. Translational medicine endeavors to bring basic re-
searchers and clinicians together in a common space where great dis-
coveries in the laboratory can be applied directly and rapidly in the
clinic. The ﬁeld also depends on the input and feedback from those at
the forefront of clinical care—their daily observations in the clinic
being critical for both detecting the emergence of new public health
concerns and communicating the progress of new treatmentmodalities.
Translational research is therefore inherently bidirectional and far
reaching in its scope and applications.
We live at a timewhen a highly pathogenic viral epidemic appears to
be spiraling out of control, with no clear resolution in sight. But, we also
live in an era with unprecedented resources to combat this threat and
others like it. With the launch of EBioMedicine, we hope to serve both
the clinical and basic research communities by offering a multimedia
platform to facilitate dialogue where scientiﬁc ideas and clinical needs
can be deﬁned, experimentally explored, and ultimately solved.
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